Blood eosinophils predict inhaled fluticasone response in bronchiectasis
The use of inhaled corticosteroids (ICS) in patients with bronchiectasis is matter of debate [1]. International registries report up to 42% of bronchiectasis patients receiving ICS, although several guidelines recommend their prescription only in the presence of specific comorbidities (e.g., Allergic Bronchopulmonary Aspergillosis -ABPA-, asthma, COPD, and inflammatory bowel disease) or of eosinophilic inflammation [2,3]. Assessment of eosinophil counts in sputum is not considered, to date, a standard of care. Blood eosinophils have been shown to be a predictor of ICS response in COPD and asthma [4,5].
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Prof. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work; .Dr. Aliberti reports grants and personal fees from Bayer Healthcare, grants and personal fees from Aradigm Corporation, grants and personal fees from Grifols, personal fees from Astra Zeneca, personal fees from Basilea, personal fees from Zambon, personal fees from Novartis, personal fees from Raptor, grants and personal fees from Chiesi, personal fees from Actavis UK Ltd, personal fees from Horizon, grants and personal fees from INSMED, outside the submitted work.
Conflict of interest: Dr. Sotgiu has nothing to disclose.
Conflict of interest: Dr. BLASI reports personal fees from ASTRAZENECA, grants from BAYER, grants and personal fees from CHIESI, personal fees from GSK, personal fees from GUIDOTTI MALESCI, personal fees from GRIFOLS, grants and personal fees from INSMED, personal fees from MENARINI, personal fees from NOVARTIS, personal fees from PFIZER, personal fees from SANOFI, personal fees from ZAMBON, outside the submitted work.
Conflict of interest: Dr. Saderi has nothing to disclose.
Conflict of interest: Dr Posadas has not any conflict of interest to declare
Conflict of interest: Dr. Martinez-Garcia has received grants and fees from Zambon, Chiesi, Vitalire, Grifols, Novartis and TEVA
- Received February 27, 2020.
- Accepted May 3, 2020.
- Copyright ©ERS 2020